164 related articles for article (PubMed ID: 15378690)
1. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431.
Castagna A; Antonioli P; Astner H; Hamdan M; Righetti SC; Perego P; Zunino F; Righetti PG
Proteomics; 2004 Oct; 4(10):3246-67. PubMed ID: 15378690
[TBL] [Abstract][Full Text] [Related]
2. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiles in the cellular response to a multinuclear platinum complex.
Gatti L; Beretta GL; Carenini N; Corna E; Zunino F; Perego P
Cell Mol Life Sci; 2004 Apr; 61(7-8):973-81. PubMed ID: 15095017
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
[TBL] [Abstract][Full Text] [Related]
5. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells.
Beretta GL; Gatti L; Tinelli S; Corna E; Colangelo D; Zunino F; Perego P
Biochem Pharmacol; 2004 Jul; 68(2):283-91. PubMed ID: 15194000
[TBL] [Abstract][Full Text] [Related]
6. The role of caspase family protease, caspase-3 on cisplatin-induced apoptosis in cisplatin-resistant A431 cell line.
Mese H; Sasaki A; Nakayama S; Alcalde RE; Matsumura T
Cancer Chemother Pharmacol; 2000; 46(3):241-5. PubMed ID: 11021742
[TBL] [Abstract][Full Text] [Related]
7. Proteomic identification of predictive tissue biomarkers of sensitive to neoadjuvant chemotherapy in squamous cervical cancer.
Guo L; Zhang C; Zhu J; Yang Y; Lan J; Su G; Xie X
Life Sci; 2016 Apr; 151():102-108. PubMed ID: 26947588
[TBL] [Abstract][Full Text] [Related]
8. Impact of cisplatin administration on protein expression levels in renal cell carcinoma: a proteomic analysis.
Vasko R; Mueller GA; von Jaschke AK; Asif AR; Dihazi H
Eur J Pharmacol; 2011 Nov; 670(1):50-7. PubMed ID: 21924258
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin and oxaliplatin cytotoxic effects in sensitive and cisplatin-resistant human cervical tumor cells: time and mode of application dependency.
Martelli L; Ragazzi E; Di Mario F; Basato M; Martelli M
Anticancer Res; 2009 Oct; 29(10):3931-7. PubMed ID: 19846931
[TBL] [Abstract][Full Text] [Related]
10. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance.
Lanzi C; Perego P; Supino R; Romanelli S; Pensa T; Carenini N; Viano I; Colangelo D; Leone R; Apostoli P; Cassinelli G; Gambetta RA; Zunino F
Biochem Pharmacol; 1998 Apr; 55(8):1247-54. PubMed ID: 9719480
[TBL] [Abstract][Full Text] [Related]
11. Comparative proteomic analysis of the esophageal squamous carcinoma cell line EC109 and its multi-drug resistant subline EC109/CDDP.
Wen J; Zheng B; Hu Y; Zhang X; Yang H; Li Y; Zhang CY; Luo KJ; Zang X; Li YF; Guan XY; Fu JH
Int J Oncol; 2010 Jan; 36(1):265-74. PubMed ID: 19956855
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
Ling YH; Donato NJ; Perez-Soler R
Cancer Chemother Pharmacol; 2001 Jun; 47(6):473-80. PubMed ID: 11459199
[TBL] [Abstract][Full Text] [Related]
13. Analysis of cellular sensitization with cisplatin-induced apoptosis by glucose-starved stress in cisplatin-sensitive and -resistant A431 cell line.
Mese H; Sasaki A; Nakayama S; Yokoyama S; Sawada S; Ishikawa T; Matsumura T
Anticancer Res; 2001; 21(2A):1029-33. PubMed ID: 11396136
[TBL] [Abstract][Full Text] [Related]
14. The proteomic analysis of cisplatin resistance in breast cancer cells.
Smith L; Welham KJ; Watson MB; Drew PJ; Lind MJ; Cawkwell L
Oncol Res; 2007; 16(11):497-506. PubMed ID: 18306929
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line.
Mese H; Ueyama Y; Suzuki A; Nakayama S; Sasaki A; Hamakawa H; Matsumura T
Chemotherapy; 2001; 47(2):136-42. PubMed ID: 11173816
[TBL] [Abstract][Full Text] [Related]
16. Defining targets of modulation of human tumor cell response to cisplatin.
Beretta GL; Gatti L; Corna E; Carenini N; Zunino F; Perego P
J Inorg Biochem; 2008 Jul; 102(7):1406-15. PubMed ID: 18279962
[TBL] [Abstract][Full Text] [Related]
17. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of cisplatin-resistant human epidermoid carcinoma cell line, A431 cell.
Mese H; Sasaki A; Alcalde RE; Nakayama S; Matsumura T
Chemotherapy; 1998; 44(6):414-20. PubMed ID: 9755302
[TBL] [Abstract][Full Text] [Related]
20. MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.
Kong LR; Chua KN; Sim WJ; Ng HC; Bi C; Ho J; Nga ME; Pang YH; Ong WR; Soo RA; Huynh H; Chng WJ; Thiery JP; Goh BC
Mol Cancer Ther; 2015 Jul; 14(7):1750-60. PubMed ID: 25939760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
